Immune Checkpoint Inhibitor-Induced Pure Red Cell Aplasia: A Review of 2 Cases in Metastatic Melanoma

Keyphrases

• Acute Anemia 11%
• Adverse Reactions 55%
• Alternative Therapeutics 11%
• Best Response 11%
• Bone Marrow 11%
• Bone Marrow Biopsy 22%
• Finishing Treatments 11%
• Hematologic 55%
• Hematological Complications 11%
• High Mortality 11%
• Immune Checkpoint Inhibitor Therapy 33%
• Immune Checkpoint Inhibitor Treatment 11%
• Immune Checkpoint Inhibitors 100%
• Immune Thrombocytopenia 11%
• Immunosuppressive Therapy 11%
• Ipilimumab 11%
• Malignancy 11%
• Metastatic Melanoma 100%
• Mortality Risk 11%
• Nivolumab 11%
• Novel Treatments 11%
• Primary Tumor 11%
• Pure Red Cell Aplasia 100%
• Rare Diseases 11%
• Reaction Types 11%
• Rechallenge 22%
• Response to Immunotherapy 11%
• Response to Treatment 11%
• Steroid Therapy 11%
• Therapeutic Potential 11%

Medicine and Dentistry

• Adverse Event 38%
• Anemia 7%
• Awareness 7%
• Bone Marrow Biopsy 15%
• Cancer 7%
• Ciprofloxacin 7%
• Clinician 7%
• Idiopathic Thrombocytopenic Purpura 7%
• Immune Checkpoint Inhibitor 100%
• Immunosuppressive Treatment 7%
• Immunotherapy 15%
• Ipilimumab 7%
• Metastatic Melanoma 100%
• Nivolumab 7%
• Primary Tumor 7%
• Pure Red Cell Aplasia 100%
• Rare Disease 7%
• Recurrent Disease 7%
• Steroid Therapy 7%